Bio


Dr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich), where he gained his first experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he worked on molecular evolution. Dr. Hugenmatter then spent 11 years as a research scientist and team leader at Roche. During that time he developed and optimized several antibody lead candidates for therapeutic application in Oncology and Neuroscience. All along his career, Dr. Hugenmatter was and still is intrigued by the question how a ideal drug must look like to give the maximal benefit to the patient.

Academic Appointments


Honors & Awards


  • Roche Innovator Award, Roche (2014)
  • Fellowship, Swiss Friends of the Weizmann Institute of Science (2007)

Patents


  • Petra Rueger, Georg Tiefenthaler, Ekkehard Moessner, Jens Niewoehner, Adrian Hugenmatter, Cuiying shao, Francesca Ros, Gang Xu. "United States Patent US2017051071A1 Monovalent Blood Brain Barrier Shuttle Modules", Hoffmann-La Roche Inc., Jul 6, 2016
  • Stefan Dengl, Thomas Emrich, Guy Geroges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady. "United States Patent US2016376352A1 Humanzed Anti-Tau(pS422) Antibodies and Methods of Use", Hoffmann-La Roche Inc., Jun 22, 2016
  • Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Peter Bruenker, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Adrian Hugenmatter, Christiane Jaeger, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana. "United States Patent US2017327579A1 Bispecific antibodies against CD3epsilon and BCMA", ENGMAB AG, Nov 18, 2015
  • Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umana. "United States Patent US2012282176A1 Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier", Roche Glycart AG, Nov 8, 2012